497 research outputs found

    Control of the diffusible hydrogen content in different steel phases through the targeted use of different welding consumables in underwater wet welding

    Get PDF
    Due to the rising number of offshore structures all over the world, underwater wet welding has become increasingly relevant, mainly as a repair method. Welding in direct contact with water involves numerous challenges. A topic focused by many studies is the risk of hydrogen-induced cracking in wet weldments due to hardness values of up to 500 HV 0.2 in the heat-affected zone (HAZ) and high levels of diffusible hydrogen in the weld metal. The risk of cracking increases as the equivalent carbon content rises, because the potential to form martensitic structures within the HAZ rises too. Thus, high-strength steels are especially prone to hydrogen-induced cracking and are considered unsafe for underwater wet repair weldments. © 2020 The Authors. Materials and Corrosion published by Wiley-VCH Gmb

    Elizabeth Polk Benson (13 May 1924-19 March 2018

    Get PDF
    An appreciation of the life and work of Pre-Columbian art historian Elizabeth Polk Benson.is presented from multiple points of view

    Motion of Inertial Observers Through Negative Energy

    Get PDF
    Recent research has indicated that negative energy fluxes due to quantum coherence effects obey uncertainty principle-type inequalities of the form |\Delta E|\,{\Delta \tau} \lprox 1\,. Here ΔE|\Delta E| is the magnitude of the negative energy which is transmitted on a timescale Δτ\Delta \tau. Our main focus in this paper is on negative energy fluxes which are produced by the motion of observers through static negative energy regions. We find that although a quantum inequality appears to be satisfied for radially moving geodesic observers in two and four-dimensional black hole spacetimes, an observer orbiting close to a black hole will see a constant negative energy flux. In addition, we show that inertial observers moving slowly through the Casimir vacuum can achieve arbitrarily large violations of the inequality. It seems likely that, in general, these types of negative energy fluxes are not constrained by inequalities on the magnitude and duration of the flux. We construct a model of a non-gravitational stress-energy detector, which is rapidly switched on and off, and discuss the strengths and weaknesses of such a detector.Comment: 18pp + 1 figure(not included, available on request), in LATEX, TUPT-93-

    Basic concepts of fluid responsiveness

    Get PDF
    Predicting fluid responsiveness, the response of stroke volume to fluid loading, is a relatively novel concept that aims to optimise circulation, and as such organ perfusion, while avoiding futile and potentially deleterious fluid administrations in critically ill patients. Dynamic parameters have shown to be superior in predicting the response to fluid loading compared with static cardiac filling pressures. However, in routine clinical practice the conditions necessary for dynamic parameters to predict fluid responsiveness are frequently not met. Passive leg raising as a means to alter biventricular preload in combination with subsequent measurement of the change in stroke volume can provide a fast and accurate way to guide fluid management in a broad population of critically ill patients

    Air fluorescence measurements in the spectral range 300-420 nm using a 28.5 GeV electron beam

    Full text link
    Measurements are reported of the yield and spectrum of fluorescence, excited by a 28.5 GeV electron beam, in air at a range of pressures of interest to ultra-high energy cosmic ray detectors. The wavelength range was 300 - 420 nm. System calibration has been performed using Rayleigh scattering of a nitrogen laser beam. In atmospheric pressure dry air at 304 K the yield is 20.8 +/- 1.6 photons per MeV.Comment: 29 pages, 10 figures. Submitted to Astroparticle Physic

    Darwin -— an experimental astronomy mission to search for extrasolar planets

    Get PDF
    As a response to ESA call for mission concepts for its Cosmic Vision 2015–2025 plan, we propose a mission called Darwin. Its primary goal is the study of terrestrial extrasolar planets and the search for life on them. In this paper, we describe different characteristics of the instrument

    Prenatal exposure to traffic and ambient air pollution and infant weight and adiposity: The Healthy Start study

    Get PDF
    Background: Prenatal exposures to ambient air pollution and traffic have been associated with adverse birth outcomes, and may also lead to an increased risk of obesity. Obesity risk may be reflected in changes in body composition in infancy. Objective: To estimate associations between prenatal ambient air pollution and traffic exposure, and infant weight and adiposity in a Colorado-based prospective cohort study. Methods: Participants were 1125 mother-infant pairs with term births. Birth weight was recorded from medical records and body composition measures (fat mass, fat-free mass, and adiposity [percent fat mass]) were evaluated via air displacement plethysmography at birth (n = 951) and at ~5 months (n = 574). Maternal residential address was used to calculate distance to nearest roadway, traffic density, and ambient concentrations of fine particulate matter (PM2.5) and ozone (O3) via inverse-distance weighted interpolation of stationary monitoring data, averaged by trimester and throughout pregnancy. Adjusted linear regression models estimated associations between exposures and infant weight and body composition. Results: Participants were urban residents and diverse in race/ethnicity and socioeconomic status. Average ambient air pollutant concentrations were generally low; the median, interquartile range (IQR), and range of third trimester concentrations were 7.3 μg/m3 (IQR: 1.3, range: 3.3–12.7) for PM2.5 and 46.3 ppb (IQR: 18.4, range: 21.7–63.2) for 8-h maximum O3. Overall there were few associations between traffic and air pollution exposures and infant outcomes. Third trimester O3 was associated with greater adiposity at follow-up (2.2% per IQR, 95% CI 0.1, 4.3), and with greater rates of change in fat mass (1.8 g/day, 95% CI 0.5, 3.2) and adiposity (2.1%/100 days, 95% CI 0.4, 3.7) from birth to follow-up. Conclusions: We found limited evidence of an association between prenatal traffic and ambient air pollution exposure and infant body composition. Suggestive associations between prenatal ozone exposure and early postnatal changes in body composition merit further investigation

    Measurement of Pressure Dependent Fluorescence Yield of Air: Calibration Factor for UHECR Detectors

    Full text link
    In a test experiment at the Final Focus Test Beam of the Stanford Linear Accelerator Center, the fluorescence yield of 28.5 GeV electrons in air and nitrogen was measured. The measured photon yields between 300 and 400 nm at 1 atm and 29 deg C are Y(760 Torr, air) = 4.42 +/- 0.73 and Y(760 Torr, nitrogen) = 29.2 +/- 4.8 photons per electron per meter. Assuming that the fluorescence yield is proportional to the energy deposition of a charged particle traveling through air, good agreement with measurements at lower particle energies is observed.Comment: 22 pages, 14 figures, 2 tables, submitted to Astroparticle Physic

    Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

    Get PDF
    IMPORTANCE Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. OBJECTIVE To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. DESIGN, SETTING, AND PARTICIPANTS CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were randomized between January 4 and September 26, 2016. Treatment group information was blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia, Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A and 49 each to arms B and C). INTERVENTIONS Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C). MAIN OUTCOMES AND MEASURES Coprimary end points were safety, tolerability, and objective response rate. Duration of response was also measured (investigator assessed with the Response Evaluation Criteria in Solid Tumors v1.1). RESULTS Of 148 total participants, 120 were male (81%). Median (IQR) age was 60 (52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR, 29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median (range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months (4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A; grade 5 pneumonitis). CONCLUSIONS AND RELEVANCE In this randomized clinical trial, nivolumab plus ipilimumab had manageable safety, promising objective response rate, and durable responses. The arm A regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) received accelerated approval in the US based on the results of this study. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0165887
    corecore